FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285304530> ?p ?o ?g. }

• W4285304530 endingPage "22" @default.
• W4285304530 startingPage "15" @default.
• W4285304530 abstract "El vericiguat, un estimulador oral de la guanilato ciclasa soluble de administración una vez al día, se ha estudiado ampliamente en pacientes con insuficiencia cardiaca y fracción de eyección reducida (IC-FEr). El estudio VICTORIA es un ensayo clínico de fase 3 que comparó frente a placebo el vericiguat añadido al tratamiento recomendado por las guías, en 5.050 pacientes sintomáticos con IC-FEr y una descompensación reciente de la IC (hospitalización por IC en los 6 meses previos o necesidad de diuréticos intravenosos en los 3 meses previos), que representan a una población en alto riesgo y vulnerable no bien caracterizada en otros ensayos clínicos. En ese estudio, el vericiguat redujo significativamente el riesgo de la variable primaria combinada de muerte cardiovascular o primera hospitalización por IC, con un excelente perfil de seguridad. En comparación con otros ensayos clínicos de IC-FEr, como el PARADIGM-HF, DAPA-HF, EMPEROR-REDUCED o GALACTIC-HF, los pacientes incluidos en el VICTORIA eran mayores, estaban más sintomáticos y tenían concentraciones de péptidos natriuréticos más altas. En términos absolutos, en comparación con estos estudios, los resultados del VICTORIA fueron similares o incluso mejores en algunos casos. Por lo tanto, el vericiguat proporciona beneficios adicionales en el abordaje de esta población. Vericiguat, a once-daily oral stimulator of soluble guanylyl cyclase, has been studied extensively in patients with heart failure with reduced ejection fraction (HFrEF). The VICTORIA study was a phase-3 trial that compared vericiguat with placebo, given in addition to guideline-recommended therapy, in 5050 symptomatic HFrEF patients and recent decompensated heart failure (i.e. heart failure-related hospitalization in the previous 6 months or the need for intravenous diuretics in the previous 3 months). These patients constitute a high-risk, vulnerable population that has not been well characterized in other clinical trials. In the VICTORIA study, vericiguat significantly reduced the risk of the combined primary end point of cardiovascular death or first hospitalization for heart failure. The safety profile was excellent. Compared with patients in other HFrEF clinical trials, such as the PARADIGM-HF, DAPA-HF, EMPEROR- Reduced and GALACTIC-HF trials, those in the VICTORIA trial were older, had more symptoms, and had higher natriuretic peptide levels. Overall, the results of the VICTORIA trial were similar to those of other studies but were even better in some cases. Consequently, vericiguat offers additional benefits in the management of this patient population." @default.
• W4285304530 created "2022-07-14" @default.
• W4285304530 creator A5000996407 @default.
• W4285304530 creator A5045256592 @default.
• W4285304530 creator A5056316345 @default.
• W4285304530 creator A5079243550 @default.
• W4285304530 creator A5092315790 @default.
• W4285304530 date "2022-01-01" @default.
• W4285304530 modified "2023-10-18" @default.
• W4285304530 title "Vericiguat: resultados del estudio VICTORIA" @default.
• W4285304530 cites W2061188498 @default.
• W4285304530 cites W2113698123 @default.
• W4285304530 cites W2113835063 @default.
• W4285304530 cites W2153739004 @default.
• W4285304530 cites W2191722017 @default.
• W4285304530 cites W2592176942 @default.
• W4285304530 cites W2735903438 @default.
• W4285304530 cites W2761635900 @default.
• W4285304530 cites W2800434402 @default.
• W4285304530 cites W2809850559 @default.
• W4285304530 cites W2913885036 @default.
• W4285304530 cites W2915620466 @default.
• W4285304530 cites W2974260792 @default.
• W4285304530 cites W3000607175 @default.
• W4285304530 cites W3013207865 @default.
• W4285304530 cites W3013323219 @default.
• W4285304530 cites W3013617526 @default.
• W4285304530 cites W3030846837 @default.
• W4285304530 cites W3047295367 @default.
• W4285304530 cites W3081830235 @default.
• W4285304530 cites W3091802911 @default.
• W4285304530 cites W3092112220 @default.
• W4285304530 cites W3092297248 @default.
• W4285304530 cites W3093335049 @default.
• W4285304530 cites W3094067118 @default.
• W4285304530 cites W3096425772 @default.
• W4285304530 cites W3098430919 @default.
• W4285304530 cites W3098774101 @default.
• W4285304530 cites W3120072441 @default.
• W4285304530 cites W3139506724 @default.
• W4285304530 cites W3154225495 @default.
• W4285304530 cites W3162755126 @default.
• W4285304530 cites W3164482676 @default.
• W4285304530 cites W3165321986 @default.
• W4285304530 cites W3176838616 @default.
• W4285304530 cites W3177541422 @default.
• W4285304530 cites W3184465454 @default.
• W4285304530 cites W3193598686 @default.
• W4285304530 cites W3194683466 @default.
• W4285304530 cites W3196153542 @default.
• W4285304530 cites W4226217602 @default.
• W4285304530 cites W82015992 @default.
• W4285304530 doi "https://doi.org/10.1016/s1131-3587(22)00003-6" @default.
• W4285304530 hasPublicationYear "2022" @default.
• W4285304530 type Work @default.
• W4285304530 citedByCount "0" @default.
• W4285304530 crossrefType "journal-article" @default.
• W4285304530 hasAuthorship W4285304530A5000996407 @default.
• W4285304530 hasAuthorship W4285304530A5045256592 @default.
• W4285304530 hasAuthorship W4285304530A5056316345 @default.
• W4285304530 hasAuthorship W4285304530A5079243550 @default.
• W4285304530 hasAuthorship W4285304530A5092315790 @default.
• W4285304530 hasConcept C142362112 @default.
• W4285304530 hasConcept C15708023 @default.
• W4285304530 hasConcept C71924100 @default.
• W4285304530 hasConceptScore W4285304530C142362112 @default.
• W4285304530 hasConceptScore W4285304530C15708023 @default.
• W4285304530 hasConceptScore W4285304530C71924100 @default.
• W4285304530 hasLocation W42853045301 @default.
• W4285304530 hasOpenAccess W4285304530 @default.
• W4285304530 hasPrimaryLocation W42853045301 @default.
• W4285304530 hasRelatedWork W1506200166 @default.
• W4285304530 hasRelatedWork W1995515455 @default.
• W4285304530 hasRelatedWork W2039318446 @default.
• W4285304530 hasRelatedWork W2048182022 @default.
• W4285304530 hasRelatedWork W2080531066 @default.
• W4285304530 hasRelatedWork W2604872355 @default.
• W4285304530 hasRelatedWork W2748952813 @default.
• W4285304530 hasRelatedWork W2899084033 @default.
• W4285304530 hasRelatedWork W3032375762 @default.
• W4285304530 hasRelatedWork W3108674512 @default.
• W4285304530 hasVolume "22" @default.
• W4285304530 isParatext "false" @default.
• W4285304530 isRetracted "false" @default.
• W4285304530 workType "article" @default.